Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. - Wikidata - awgldk - TriplyDB

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

http://www.wikidata.org/entity/Q34042870

about

Long-term intermittent pharmacological therapy of uterine fibroids - a possibility to avoid hysterectomy and its negative consequences Ulipristal acetate for fibroids Clinical utility of ulipristal acetate for the treatment of uterine fibroids: current evidence.Epidemiology of Uterine Fibroids: From Menarche to Menopause.Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development.Urological complications of uterine leiomyoma: a review of literature.An observation study of the clinical evaluation of symptom relief and side effects associated with taking ulipristal acetate (esmya) including its effect on pre-menstrual syndrome.Selective progesterone receptor modulators (SPRMs) for uterine fibroids.Uterine fibroid management: from the present to the future.Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.Molecular targets of dietary phytochemicals for possible prevention and therapy of uterine fibroids: Focus on fibrosis.Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women.Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.Clinical correlates of leiomyoma estrogen and progesterone receptors among Nigerian women.Current Practices for Treatment of Uterine Fibroids.Adverse obstetric outcomes in pregnant women with uterine fibroids in China: A multicenter survey involving 112,403 deliveries.Repeated intermittent ulipristal acetate in the treatment of uterine fibroids: a cost-effectiveness analysis.Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.Successes and failures of uterine leiomyoma drug discovery.Selective progesterone receptor modulators: current applications and perspectives.Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial.Unexpected uterine leiomyosarcoma in a woman with multiple myomas treated with ulipristal acetate: case report and literature review.Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.Esmya® and the PEARL studies: A review.Ulipristal acetate as a treatment option for uterine fibroids.Bisphenol A Concentrates Preferentially in Human Uterine Leiomyoma and Induces Proliferation in Rat Myometrium.Current medical treatment of uterine fibroids.Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice.Fibroid Complications in Pregnancy Clinical and Economic Management of Uterine Fibroids: The Point of View of a Decision Makers Board

P2860

Q26751927-D97212A4-9CEC-4191-A83D-527F6C31F95B Q28080041-EB49580A-00A1-4190-9346-CF3A23C27257 Q35240186-187D7D96-C0D1-45E8-B2DE-70CAA82C73A3 Q36522644-C4F03F8F-FF2E-41F8-A11C-827D7467F19D Q36525065-1DD1359C-09CE-4F67-A150-F9A61527CED6 Q37564411-23FC8400-B0D7-44C6-88D6-4EEC55DC90AF Q37647346-B27F6835-FB39-41DA-A905-798262805DE4 Q38569796-0CB9DAEE-2B5B-4A11-8D2C-76B9CAD8240B Q38752901-F0A988CD-A5F5-4F5D-928E-9EB95166DD7F Q38789764-93F861C5-7F63-4F62-87BA-F9646D0451B3 Q38819001-2293B916-CA5D-409F-BE2A-2FADEF382F51 Q38837038-09DBD181-5422-48F4-8B29-821395C5F5B8 Q38980489-58831BE5-704B-4E07-9153-61AB1BA104B7 Q39369473-13557242-9562-4775-9CD9-311F4EDA5FA7 Q41633470-BAA2D93F-E3C5-4ACB-80AD-638AB37E47D7 Q46560230-F452DE90-CB48-4A49-8947-2BE93BC91155 Q46949231-D2CBFA33-73B8-4514-B107-2FDA59286019 Q47128772-A7A30863-5B68-436D-A2D1-D67302558772 Q47136481-DC9045AC-433C-421E-BB15-3DC747175875 Q47160345-38A59716-150D-4E13-86CA-9EEC3188F0B3 Q47282567-CF57269E-EA89-4F67-99D7-BC770C94D489 Q47562528-F8F4EA2A-3046-47CE-8726-76C55D17B19B Q47729672-FD72E1F4-978E-4C34-8C65-107FF6AF153C Q47773596-812402FC-FE61-4408-80C2-46ED6AC83D40 Q47950025-A7AE628A-9F67-4F75-9F0B-0C2D7A28D4C6 Q47993482-F7E588DD-AE59-4FA2-AA7D-BBB47D781C5C Q50047282-67ADBE75-0FC6-4959-BD69-CF6E2C3CF3B7 Q50331802-8586B453-E27E-4A32-9837-F1E75FAEB475 Q50974309-7F6FFD3A-386F-4A49-81EB-6BE96094C4C9 Q51736809-A84637D3-B6D9-42A2-AE88-960929255E10 Q52609438-0DA3955A-8838-4F72-BB68-9538D7AC815F Q53101697-588D6942-5CC2-4175-9C9D-2155C988A48E Q57600559-C5ADFA88-A3BA-4CF6-9603-912CBE2B6FFB

P2860

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

http://www.wikidata.org/entity/Q34042870

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@ast

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@en

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@nl

type

label

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@ast

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@en

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@nl

prefLabel

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@ast

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@en

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids.

@nl

P1433

Q34042870-6160F9D5-B1AD-41A8-9EF7-8279C53CAE08

P1476

Q34042870-0A1EE416-ABDB-44D9-AB2F-1A6684B7A335

P2093

Q34042870-2171230A-4600-4028-963E-5D4DA27705A1

Q34042870-271FADB6-7699-4624-811B-5387C9B4800C

Q34042870-43BEECF0-01CF-41D4-B5D0-6B5AD6028562

Q34042870-4C295543-D1DA-49DD-B6AC-A823E003860D

Q34042870-5B2D1DAE-2850-4926-B55A-5DAB4C740DC2

Q34042870-70A8AAA8-9E2A-4CA8-9B98-11DB20411850

Q34042870-7C8232C8-FFE5-4CB2-99CA-C828531DEA2F

Q34042870-7EBA2771-E1CC-43A1-8072-30829F0CF4B3

Q34042870-7EF4D80B-1758-4419-BBE2-62366A077418

Q34042870-9B70D1E6-4804-4FA2-80CA-423A325FCD4B

P304

Q34042870-E6C2CBDA-9606-44C9-9A41-42B1A2EF7A3F

P31

Q34042870-18369971-AE0E-403D-AAC6-8E3D949932F1

P356

Q34042870-C6C65BE0-358E-4D20-A7BF-655AF4C885EC

P407

Q34042870-32D30EA9-BEF3-4BE5-9820-BE64C6155D21

P433

Q34042870-E662B5D3-D9D0-4AB0-A9E7-0FCECDFA5D3B

P478

Q34042870-5C9CF55F-E58E-40C4-A596-2EB770194BFB

P50

Q34042870-6CB207C3-C105-470C-8BEC-112C0FB43DBE

Q34042870-BA0B5666-5C42-41BB-BEAC-2EC1FDB6A1EE

P577

Q34042870-506F2D64-6116-4515-8B59-950D4469EA57

P5875

Q34042870-51DD2215-74A3-4B34-AE94-57FD9765F1BF

P698

Q34042870-5F317302-96D8-49B3-9A5F-5BB89BF9683F

P356

J.FERTNSTERT.2014.10.038

P1433

Fertility and Sterility

P1476

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids

@en

P2093

Bart C J M Fauser

http://www.w3.org/2001/XMLSchema#string

Dace Matule

http://www.w3.org/2001/XMLSchema#string

David H Barlow

http://www.w3.org/2001/XMLSchema#string

Elke Bestel

http://www.w3.org/2001/XMLSchema#string

Ernest Loumaye

http://www.w3.org/2001/XMLSchema#string

Hans-Joachim Arhendt

http://www.w3.org/2001/XMLSchema#string

Ian Osterloh

http://www.w3.org/2001/XMLSchema#string

Janos Zatik

http://www.w3.org/2001/XMLSchema#string

Mihai Cristian Dumitrascu

http://www.w3.org/2001/XMLSchema#string

Olivier Donnez

http://www.w3.org/2001/XMLSchema#string

P304

519-27.e3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.FERTNSTERT.2014.10.038

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Hervé Fernandez

P577

2014-12-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270106726

http://www.w3.org/2001/XMLSchema#string

P698

25542821

http://www.w3.org/2001/XMLSchema#string